Novo Nordisk Q4 profit beats expectations, sees slower growth in 2025

The Local - Dk

Lean Left

Factuality

Ownership

Danish weight-loss drugmaker Novo Nordisk posts huge profit jump

Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said on Wednesday its net profit jumped 21 percent in 2024 to 100 billion Danish kroner ($13.9 billion).

The Independent

perspectivemedia.com

View article

Reposted by

perspectivemedia.com

Lean Left

Factuality

Ownership

Wegovy obesity drug sales more than double but set to slow

Sales of Wegovy, a prescription weight loss injection, surged to 19.9 billion Danish kroner (£2.2 billion) in the fourth quarter of last year.

Financial Times

Center

Factuality

Ownership

Obesity drug sales help Novo Nordisk beat expectations

Danish pharma group expects sales growth to slow this year

Aftonbladet

Left

Factuality

Ownership

Danish pharmaceutical giant Novo Nordisk, known for the diet drugs Ozempic and Wegovy, reports full-year sales that beat market expectations. – It is

Jyllands-Posten

Lean Right

Factuality

Ownership

The earnings of the Danish pharmaceutical company Novo Nordisk have grown at double-digit growth rates in recent years. And in 2024 the company reached another milestone. Here the profit is 101 billion kroner, ...

Reuters

Investing.com

Center

View article

regionalmedianews.com

View article

Market Screener

Center

View article

+3 Reposted by 3 other sources

Center

Factuality

Ownership

Novo Nordisk Q4 profit beats expectations, sees slower growth in 2025

Wegovy maker Novo Nordisk on Wednesday forecast slower sales growth for 2025 than 2024, a blow that is likely to deepen investor concerns that the company is losing its edge in the competitive obesity market to rival Eli Lilly .